Company Overview and News

1
TWNK / Hostess Brands, Inc. Class A - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-17 fintel.io
Hostess Brands, Inc. Class A (NASDAQ:TWNK) has 152 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 135,595,371 shares. Largest shareholders include Wellington Management Group Llp, Gores Sponsor Llc, Henderson Group Plc, Northwestern Mutual Investment Management Company, Llc, and Vanguard Group Inc.

 
Hong Kong trade show in KL to feature innovative products

2017-11-04 thestar.com.my
Sing Sing Rabbit, without the rabbit head, is a mysterious girl who has her mask on wherever she goes. She made an appearance to introduce her merchandise at the Sigema flagship store in Langham Place, Mong Kok, Hong Kong

1
JOE / St. Joe Co. (THE) - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-04 fintel.io
St. Joe Co. (THE) (NYSE:JOE) has 106 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 38,556,953 shares. Largest shareholders include BlackRock Inc., Henderson Group Plc, Vanguard Group Inc, Price T Rowe Associates Inc /md/, and Brandes Investment Partners, Lp.

 
NICE / NICE Systems Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-10-31 fintel.io
NICE Systems Ltd. (NASDAQ:NICE) has 172 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32,464,139 shares. Largest shareholders include Henderson Group Plc, Janus Capital Management Llc, Massachusetts Financial Services Co /ma/, Migdal Insurance & Financial Holdings Ltd., and Oppenheimer Funds Inc.

1
DBVT / DBV Technologies S.A. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-10-31 fintel.io
DBV Technologies S.A. (NASDAQ:DBVT) has 78 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 25,985,143 shares. Largest shareholders include Baker Brothers Advisors LP, FMR LLC / Fidelity Management & Research, Henderson Group Plc, Janus Capital Management Llc, and Perceptive Advisors Llc.

 
Bond King Bill Gross Falls to the Middle of the Pack - Bloomberg

2017-09-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
WEX / WEX Inc. - Institutional Ownership - Fintel.io

2017-09-12 fintel.io
WEX Inc. (NYSE:WEX) has 233 institutional investors that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 44,974,939 shares. Major holders include Henderson Group Plc, Wellington Management Group Llp, Jp Morgan Chase & Co, Vanguard Group Inc, and BlackRock Inc..

 
Henderson Group Plc discloses 10.10% ownership in WEX / WEX Inc. - Fintel.io

2017-09-12 fintel.io
September 11, 2017 - Henderson Group Plc has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,352,065 shares of WEX Inc. (NYSE:WEX). This represents 10.1 percent ownership of the company.

 
AMC / AMC Entertainment Holdings, Inc. - Institutional Ownership - Fintel.io

2017-09-08 fintel.io
AMC Entertainment Holdings, Inc. (NYSE:AMC) has 179 institutional investors that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 61,288,485 shares. Major holders include RidgeWorth Capital Management LLC, Vanguard Group Inc, Schroder Investment Management Group, BlackRock Inc., and Henderson Group Plc.

 
Final Results

2017-08-10 londonstockexchange
The Company aims to maximise shareholders' total returns (capital and income) by investing in smaller companies that are quoted in the United Kingdom.

 
Australian investment Ideas - Australia's Economy Still Strong

2017-07-24 valuewalk
Australian Real Estate is running out of steam, but UBS does not see Australia’s economy crashing…yet. updated on 7/24/2017 at 8:25AM EST

 
Half-year Report

2017-07-13 londonstockexchange
The Company aims to provide investors with an attractive total return, focused on growing both capital and income for shareholders.

 
Directorate Changes

2017-07-05 londonstockexchange
As reported on 12 May 2017, Jim Durkin, the Company's Chief Executive Officer had informed the Company of his intention to retire from the Company.  The Company has since undertaken a search for a successor to Jim Durkin.

 
Half-year Report

2017-06-19 londonstockexchange
1 The net gearing percentage reflects the amount of borrowings (bank loans or overdrafts) the Company has used to invest in the market less cash and investment cash funds, divided by net assets multiplied by 100.

 
Janus-Henderson Merger: The Wait Is Over

2017-06-13 marketrealist
The merger of Janus Capital Group (JNS) and Henderson Group (HGG) was announced in late 2016 and finalized on May 30, 2017. The merged entity is called Janus Henderson Group (JHG). The combined entity is now a global active asset manager with AUM (assets under management) of more than $331.0 billion. Its combined market cap (capitalization) has reached around $6.0 billion. Henderson acquired Janus Capital for about $2.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...